Let-7i inhibits the malignant phenotype of osteosarcoma cells by targeting Aurora-B

Guo Mei Zhang1, Xin Hua Long2, Jia Ming Liu2

  • 1Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.

Insights

This study reveals that let-7i microRNA targets Aurora-B, suppressing osteosarcoma cell invasion and proliferation. Restoring let-7i offers a potential therapeutic strategy for osteosarcoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Aurora-B kinase is implicated in osteosarcoma (OS) cell invasion and metastasis.
  • The precise mechanism driving Aurora-B overexpression in OS remains unclear.
  • let-7i microRNA expression is significantly downregulated in OS tissues and cells.

Purpose of the Study:

  • To investigate the regulatory role of let-7i in Aurora-B expression within osteosarcoma.
  • To explore the therapeutic potential of targeting the let-7i/Aurora-B axis in OS treatment.

Main Methods:

  • Bioinformatic analysis to predict let-7i binding sites on Aurora-B mRNA.
  • Luciferase reporter assays to validate direct targeting of Aurora-B by let-7i.
  • In vitro experiments using let-7i mimics and Aurora-B silencing (LV-shAurora-B) in OS cells.

Main Results:

  • let-7i directly targets and negatively regulates Aurora-B expression in OS cells.
  • Restoration of let-7i significantly decreased Aurora-B mRNA and protein levels.
  • let-7i mimics suppressed OS cell proliferation, migration, and invasion.
  • let-7i's inhibitory effect on malignant phenotypes was partially mediated by Aurora-B downregulation.

Conclusions:

  • let-7i acts as a tumor suppressor in osteosarcoma by targeting Aurora-B.
  • The let-7i/Aurora-B pathway represents a promising novel therapeutic target for osteosarcoma.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K